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Background: Disorders of sex development (DSD) is the term used for congenital conditions in which
development of chromosomal, gonadal, or phenotypic sex is atypical. Nuclear receptor subfamily 5, group A,
member 1 gene (NR5A1) encodes steroidogenic factor 1 (SF1), a transcription factor that is involved in gonadal
development and regulates adrenal steroidogenesis. Mutations in the NR5A1 gene may lead to different 46,XX or
46,XY DSD phenotypes with or without adrenal failure. We report a Brazilian family with a novel NR5A1 mutation
causing ambiguous genitalia in 46,XY affected individuals without Müllerian derivatives and apparently normal
Leydig function after birth and at puberty, respectively. Their mother, who is also heterozygous for the mutation,
presents evidence of primary ovarian insufficiency.
Case presentation: Three siblings with 46,XY DSD, ambiguous genitalia and normal testosterone production were
included in the study. Molecular analyses for AR, SRD5A2 genes did not reveal any mutation. However, NR5A2
sequence analysis indicated that all three siblings were heterozygous for the p.Cys65Tyr mutation which was
inherited from their mother. In silico analysis was carried out to elucidate the role of the amino acid change on the
protein function. After the mutation was identified, all sibs and the mother had been reevaluated. Basal hormone
concentrations were normal except that ACTH levels were slightly elevated. After 1 mcg ACTH stimulation test, only
the older sib showed subnormal cortisol response.
Conclusion: The p.Cys65Tyr mutation located within the second zinc finger of DNA binding domain was
considered deleterious upon analysis with predictive algorithms. The identification of heterozygous individuals
with this novel mutation may bring additional knowledge on structural modifications that may influence NR5A1
DNA-binding ability, and may also contribute to genotype-phenotype correlations in DSD. The slightly elevated ACTH
basal levels in all three patients with 46,XY DSD and the subnormal cortisol response after 1 mcg ACTH stimulation
in the older sib indicate that a long-term follow-up for adrenal function is important for these patients. Our data
reinforce that NR5A1 analysis must also be performed in 46,XY DSD patients with normal testosterone levels
without AR mutations.
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Steroidogenic factor 1 (SF1), denominated as nuclear
receptor subfamily 5 group A member 1 (NR5A1 [OMIM +
184757]), is a protein that regulates several steps of
adrenal and gonadal development [1,2]. It is encoded
by the NR5A1 gene, which is an autosomal gene mapped
to 30 kb within 9q33. The NR5A1 gene has one non-
translated exon (exon 1), six coding exons (exon 2–7) and
six introns [3,4]. The SF1 protein has 461 amino acids
divided in two zinc-finger DNA-binding domains
(DBD), a ligand-binding domain (LBD), two functional
activation domains (AF-1 and AF-2), an accessory region,
and a hinge region [5]. SF1 is extremely conserved among
species and it presents 95% overall amino acid identity
between human and mouse sequences [6].
NR5A1 is expressed in the developing urogenital ridge,
steroidogenic tissues (such as gonads, adrenals, and
placenta), hypothalamus and anterior pituitary [7-9]. In
general, it activates the expression of AMH in Sertoli
cells leading to the regression of Müllerian structures
[1,2,9]; in Leydig cells, it activates the expression of
several enzymes involved in steroidogenesis, resulting
in the virilization of external genitalia and testicular
descent [1,2,9]; and, in ovaries, NR5A1 is expressed in
the granulosa and theca cells where it regulates genes
required for ovarian steroidogenesis and follicle growth
maturation [8,9]. Genes such as: CYPs, HSD3B2, StAR,
SOX9, NR0B1, and others are among the gene targets
subject to SF1 transcriptional regulation [5]. As an es-
sential transcription regulator for adrenal and gonadal
development, SF1 is very important in sex differentiation
processes, although it also plays important physiological
roles in the central nervous system [10]. Therefore, muta-
tions in NR5A1may lead to Disorders of Sex Development
(DSD) defined as incomplete or disordered gonadal or
genital development, causing divergences between genetic
sex, gonadal sex and phenotypic sex [11,12].
p.Gly35Glu and p.Arg92Gln were the first two mutations
described in human NR5A1. They had been identified
in patients with primary adrenal insufficiency, complete
gonadal dysgenesis and Müllerian duct persistence [13,14].
Over 50 mutations have been reported mainly in 46,XY
DSD individuals with apparently normal adrenal func-
tion, but they were also found in 46,XX individuals
with primary ovarian insufficiency and normal female
phenotype and male individuals with infertility [15-19].
In addition, several reports demonstrated that NR5A1
variations might be associated with hypospadias, anorchia,
and with some cases of adrenal tumors and endometriosis
[20,21].
Such findings indicate a complex phenotype expressivity,
with different penetrance and variable inheritance pattern
for NR5A1 mutations. Therefore, it is difficult to establish
a direct phenotype-genotype correlation [22]. Recently,some authors have reported heterozygous loss-of-function
NR5A1 mutations in patients with clinical features of
androgen insensitivity syndrome (AIS) and apparently
normal Leydig and Sertoli cell function but without
mutations in the androgen receptor gene (AR) [23-25].
In this report, we describe the novel c.195G >A NR5A1
mutation identified in three siblings with 46,XY DSD.
They were born of non-consanguineous parents, and
had been brought to medical care due to ambiguous
genitalia. All of them had normal testosterone levels in
first months of life and the proband had normal male
puberty. Molecular analyses showed that the putative p.
Cys65Tyr missense was inherited from the mother, who
presented with signs of primary ovarian insufficiency.
Case presentation
Case report
The study was undertaken under an institutionally approved
ethic protocol and informed consent was obtained from
all subjects and relatives.
Three affected siblings with 46,XY DSD had been
evaluated (Figure 1A). The index case, now aged 15, was
born at term to healthy non-consanguineous parents, after
an uneventful pregnancy. He was assigned and registered
as female at birth and was referred to our service due
to ambiguous genitalia at the age of 9 months. Physical
examination revealed a 2-cm phallus, a single perineal
opening, and palpable gonads in the labioscrotal folds.
Laboratory data indicated high levels of FSH but normal
levels of LH, and a normal testosterone response to hCG
test. The karyotype was 46,XY and pelvic ultrasound
showed absence of mullerian derivatives. The medical
team presented such results to parents, who also received
psychological support. A few months later they decided
for female to male sex reassignment. The hypospadias
repair was performed when he was 1 year and 4 months
old. Puberty began spontaneously when he was 11 years
old. Hormone measurements have been performed every
year and the concentrations were always normal and high
for testosterone and FSH, respectively; whereas, LH levels,
that were initially normal, have progressively increased
(Table 1). Currently, he is at Tanner stage 4 without
hormone replacement therapy. His height is near the
target. Recent evaluation of the adrenal function indicated
that basal levels for ACTH and cortisol were, respectively,
slightly elevated and normal (Table 1). However, cortisol
response was subnormal after stimulation with 1 mcg
ACTH (Table 1).
The second sib, currently aged 7 years, was born at term
after an uneventful pregnancy. At birth he presented 2-cm
phallus, penoscrotal hypospadias and palpable gonads in
the labioscrotal folds. His karyotype was 46,XY. Pelvic
ultrasound did not show mullerian derivatives. Hormone
investigation was performed at 2 month of age and
Figure 1 Pedigree of the family and part of NR5A1 exon 3 sequencing. A) Three siblings and the mother carry the mutation c.195G > A. B)
Electropherogram showing the c.195G > A heterozygous transition leading to p.Cys65Tyr mutation.
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testosterone (Table 1). He was assigned as male and had
the hypospadias repaired. In a recent evaluation of the
adrenal function, basal levels of ACTH and cortisol
were, respectively, slightly elevated and normal (Table 1).
Upon 1 mcg ACTH stimulation, cortisol response was
normal (Table 1).
The third sib, who is currently 6 years old, was born
at term after an uneventful pregnancy with a 1.3-cm
phallus, a single perineal urogenital opening, and palpable
gonads, both in the inguinal region. He also had a normal
46,XY karyotype. Pelvic ultrasound did not show muller-
ian derivatives. At the age of 2 months, hormone levels
for FSH, LH, testosterone and dihydrotestosterone were
normal (Table 1). He was assigned as male and underwent
hypospadias repair and orchidopexy. Recent evaluation
of the adrenal function revealed slightly elevated basal
ACTH and normal basal cortisol levels (Table 1). He
also had a normal cortisol response upon 1 mcg ACTH
stimulation test (Table 1).
The 33-year-old mother had throughout hormone
evaluation after identifying the NR5A1 mutation (see
below). Hormonal results revealed high FSH, normal
to high LH and normal to low estradiol levels with
normal adrenal function (Table 1). She also reported
irregular menses and hot flushes, suggesting primary
ovarian insufficiency.
Methods
Genomic DNAs from patients and parents were purified
from peripheral leukocytes by proteinase K lysis, phenol/
chloroform extraction, and ethanol precipitation, according
to standard techniques. Sequencing of both AR (androgen
receptor) and SRD5A2 (5α-reductase) genes had been
performed as described elsewhere [26,27]. The NR5A1
exons and 5’ and 3’ untranslated flanking regions were
amplified by polymerase chain reaction (PCR) using
specific primers designed based on the normal gene
sequence (ENSG00000136931, www.ensembl.org). In-
dependent PCR fragments were purified in 1% agarosegel electrophoresis with the Wizard SV Gel and PCR
clean-up system (Promega, Madison, WI, USA), and both
sense and antisense strands were sequenced using the
BigDye Terminator v3.1 Cycle Sequencing Kit (Life
Technologies, Grand Island, NY, USA) with the same
primers used in PCR reactions. The Chromas Lite 2.0
(Technelysium Pty Ltd) and CLC Sequence Viewer v.6.8.1
free software (CLC bio) were used to analyze and compare
sequences with the reference NR5A1 sequence. Structural
analyses were performed using PDB ID: 2FF0 – chain A as
template. The native and mutant models were constructed
by SWISS MODEL web-served program. Internal contacts
were evaluated by STING Millenium (http://www.cbi.
cnptia.embrapa.br) and visualized by PyMol®.
Results
DNA sequence analyses of AR and SRD5A2 genes did not
show any mutation. However, NR5A1 gene sequencing
revealed a novel heterozygous transition G > A within
exon 3 in all three siblings as well as in their mother
(Figure 1B). The nucleotide change c.195G >A is predicted
to cause the substitution of a cysteine by a tyrosine at
the amino acid residue 65 (p.Cys65Tyr).
The cysteine residue in position 65 in the NR5A1 protein
is highly conserved across mammalian species (Figure 2A).
It is located at the second zinc finger of DNA binding
domain, as illustrated by Little et al. [28] (Figure 2B, C).
Structural analyses demonstrated that C65 in the native
protein makes a hydrogen bond with R69 and has a
hydrophobic interaction with C68 (Figure 2D). The mu-
tant Y65 maintains both interactions. However, a new
hydrophobic interaction by 3.42 Ångstroms is established
with C55 (Figure 2E).
Three predictive methods to evaluate the effect of the
amino acid substitution were used: PolyPhen (Polymorph-
ism Phenotyping) that gives scores ranging from 0 (neutral)
to a positive (damaging) number; SIFT (Sorting Intolerant
From Tolerant) whose scores range from 0 (damaging) to
1 (neutral); and Aling GV-GD that classifies the amino
acid change into classes ranging from C0 to C65, where
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Figure 2 Comparison of normal and mutant NR5A1 protein considering sequence conservation and internal aminoacid interactions.
A) Multiple alignment of NR5A1 protein family using ClustalW: the conserved residue C65 is shown in red. B) Scheme of the two zinc fingers
from the DNA-binding domain (DBD). Red circle denotes the C65 residue (adapted from Little et al. [25]). C) Structural complex of NR5A1 bound
to DNA showing the C65 residue ligated to the zinc atom at the zinc-finger binding site within the DNA binding domain. D) Structural model of
the native protein showing internal contacts. The C65 interacts by hydrogen bond with R69 and hydrophobic interaction with C68. E) Mutant
protein internal contacts. The Y65 establish new hydrophobic contact with C55.
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The p.Cys65Tyr mutation resulted in PolyPhen score of
1.0, SIFT score of 0 and Aling GV-GD put it into class
C65 indicating a protein damage, probably leading to
patients’ phenotypes. In order to discard the possibility
of the nucleotide variation being a frequent polymorph-
ism, 86 healthy controls (172 alleles) were analyzed and
c.195G > A was not identified in any allele.
Discussion
We present here the follow-up of patients with 46,XY
DSD in a Brazilian family. The three sibs presented
with different hormone profiles in the first year of life.
Testosterone levels were normal for all of them; however,
sib 1 and sib 2 presented isolated elevation of FSH and
LH levels, respectively, whereas sib 3 had normal levels
for both FSH and LH. Initially, AR and SRD5A2 genesequence analyses had been performed due to 46,XY
karyotype, ambiguous genitalia without Müllerian deriva-
tives and normal production of testosterone. As mutations
in those genes had not been identified, patients remained
idiopathic and the etiologic diagnosis was not defined,
even though the severity of ambiguous genitalia and the
familial recurrence clearly indicated a genetic origin. After
long-term follow-up, the etiology of 46,XY DSD had been
solved by the identification of p.Cys65Tyr mutation in the
NR5A1 gene which was investigated based on the recent
description of variable phenotypic expression as a result of
different NR5A1 mutations, and also based on the pos-
sibility of a mutation inheritance from a fertile mother,
which mimicked an X-linked recessive pattern [23-25].
Most 46,XY patients with NR5A1 loss-of-function muta-
tions have had biological markers that evidenced gonadal
dysgenesis, i.e.: LH and FSH levels were usually elevated,
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function, indicated by low levels of testosterone, was
invariably defective [23]. Testosterone levels in the
three patients were normal during the first year of life
and puberty development of the proband also indicated
normal Leydig cell function after birth. In addition,
Müllerian derivatives were not found suggesting that
Sertoli cell function was also normal during primary
sex differentiation. As discussed by Tantawy et al. [31],
there are very few reports on 46,XY DSD cases that had
puberty development and normal male testosterone
production inducing spontaneous virilization, however
long-term follow-up indicated a progressive gonadal
failure with elevated FSH in such cases. Although the
proband described here developed normal puberty, he
persisted with high levels of FSH from first months of
life till puberty suggesting some degree of tubular defect
that might cause fertility impairment.
Recently, Wu et al. [25] speculated if SF1 disruption
caused by NR5A1 loss-of-function mutations may be
associated with functional androgen resistance or altered
Leydig cell maturation leading to hyper-responsiveness
to postnatal LH stimulation. Our data also suggest such
a mechanism and reinforce that, in the absence of AR
mutations, NR5A1 gene analysis must be performed in
46,XY DSD despite normal testosterone levels.
Several mutations have been described in NR5A1 in
different cases of 46,XY DSD so far [15,17,32,33], how-
ever a mutation in the C65 residue has been described
here for the first time. The nucleotide change c.195G >
A results in p.Cys65Tyr missense which is predicted
as damaging by in silico tools. It is well known that
cysteine influences the overall three-dimensional structure
of proteins. Its sulfur group reacts quite readily with other
sulfur groups, forming disulfide bonds that play important
role in the folding and stability of proteins. Cysteine
residues also play a valuable role in crosslinking proteins,
which increases protein rigidity and also confers proteo-
lytic resistance [34]. Conversely, tyrosine is an aromatic
and partially hydrophobic amino acid [34]. The aromatic
side chain is usually involved in stacking interactions with
other aromatic side chains [34]. Tyrosine can also be
involved in phosphorylation within intracellular proteins
[34]. In the structural analyses, a previously inexistent
hydrophobic interaction with C55 was observed for Y65
residue. In addition, this novel mutation is located within
the second zinc finger of DNA binding domain where
C65 itself binds directly to the zinc atom [28], therefore
the change to tyrosine may influence NR5A1 DNA-binding
ability by destabilizing zinc-finger conformation. Although
functional analyses will be further necessary for formal
demonstration of a deleterious effect for p.Cys65Tyr muta-
tion, both predictive and structural analyses indicate that
it might correlate with the DSD phenotype in the threeheterozygous siblings. Their fertile 33-year-old mother who
is also heterozygous for the mutation reported irregular
menses and hot flushes, after molecular diagnosis. Upon
endocrine investigation, gonadotropin and estradiol levels
suggest primary ovarian insufficiency. Taken together,
those data indicate that p.Cys65Tyr mutation may also
compromise the ovarian functional maintenance similar
to other NR5A1 mutations described in the literature
[15-17].
Considering the slightly elevated basal ACTH levels in
all three patients with 46,XY DSD and the subnormal
cortisol response after stimulation test with 1 mcg ACTH
in the proband, it may be inferred that p.Cys65Tyr muta-
tion could have a late-onset effect upon adrenal function,
justifying a long term follow-up on such patients.
Conclusion
In conclusion, based on recent knowledge concerning the
phenotypic expression of NR5A1 mutations, the analysis
of this gene becomes an important tool not only for diag-
nosing patients with DSD including the cases with normal
testosterone secretion without AR mutations, but also
for identifying their female relatives at risk of developing
primary ovarian insufficiency and allowing reproductive
counseling as well as potentially assisted reproductive
techniques.
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